newsfilter
← Latest News
GlobeNewswire·

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with